IPO - Bellevue Life Sciences Acquisition Corp.

Form Type: S-1/A

Filing Date: 2025-06-10

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025053114

Filing Summary: OSR Holdings, Inc. has filed an amendment to its registration statement on Form S-1 as of June 10, 2025, under registration number 333-287626. This document outlines the offering of up to 15,410,000 shares of common stock, primarily for resale by the Selling Stockholder, White Lion Capital LLC, through a structured Equity Line of Credit (ELOC) agreement. OSR Holdings is a global healthcare company focused on innovative therapeutics with operations in South Korea and Switzerland, emphasizing partnerships to drive growth and product development in healthcare. The company has outlined its strategy of leveraging industry collaborations and exploring financial capital to bolster its operations. The filings indicate that White Lion may purchase shares from the company valued up to $78.9 million under the ELOC, with terms that allow for fluctuation in purchase price based on the common stock's market value. The amendment also covers the potential issuance of commitment shares and warrants tied to the investment agreements. The document includes a detailed description of the company's business model, portfolio of subsidiaries, and intellectual property holdings. The last reported price of OSR's common stock was $1.15 per share as of May 21, 2025, and discussions of significant risks and market assumptions are noted, including the company’s classification as an emerging growth company.

Form Type: S-1

Filing Date: 2025-05-28

Corporate Action: Ipo

Type: New

Accession Number: 000121390025048346

Filing Summary: OSR Holdings, Inc. has filed a registration statement on Form S-1 with the SEC on May 28, 2025, to register up to 15,410,000 shares of common stock for resale by White Lion Capital LLC, the Selling Stockholder. This includes provisions for shares issuable under an equity line agreement, a warrant agreement, and convertible notes totaling significant financial commitments. The company is classified as a smaller reporting and emerging growth company, and intends to use the raised capital for expanding its healthcare subsidiaries. Alongside its planned market approach, OSR emphasizes partnerships with industry leaders for innovative healthcare solutions and aims to enhance value through a diversified portfolio of therapeutic solutions. The anticipated market activities, along with cautions on potential dilution of shares and market variability, are detailed within the prospectus.

Form Type: DRSLTR

Filing Date: 2023-12-21

Corporate Action: Ipo

Type: New

Accession Number: 000095012323011270

Filing Summary: Bellevue Life Sciences Acquisition Corp. has submitted a draft Registration Statement on Form S-4 to the staff of the U.S. Securities and Exchange Commission for non-public review. The company intends to publicly file its registration statement along with the non-public draft submission at least 48 hours prior to any effective time and date requested. The correspondence was prepared by K&L Gates LLP and includes contact information for the firm's representative, Gary J. Kocher.